Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Tuesday, up 4.98% from the previous trading day, before settling in for the closing price of $12.25. Over the past 52 weeks, NRIX has traded in a range of $8.18-$29.56.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -38.86%. While this was happening, its average annual earnings per share was recorded -8.89%. With a float of $99.33 million, this company’s outstanding shares have now reached $101.37 million.
Nurix Therapeutics Inc (NRIX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 2.02%, while institutional ownership is 87.64%. The most recent insider transaction that took place on Nov 03 ’25, was worth 78,931. In this transaction Chief Financial Officer of this company sold 6,284 shares at a rate of $12.56, taking the stock ownership to the 37,592 shares. Before that another transaction happened on Nov 03 ’25, when Company’s Officer proposed sale 6,284 for $12.94, making the entire transaction worth $81,315.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 11/30/2024, the organization reported -0.75 earnings per share (EPS), lower than consensus estimate (set at -0.67) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.86 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.38% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.61 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
The latest stats from [Nurix Therapeutics Inc, NRIX] show that its last 5-days average volume of 1.43 million was superior to 1.0 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.66%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 73.29%, which indicates a significant decrease from 87.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.82 in the past 14 days, which was higher than the 0.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.15, while its 200-day Moving Average is $11.78. Now, the first resistance to watch is $13.34. This is followed by the second major resistance level at $13.81. The third major resistance level sits at $14.48. If the price goes on to break the first support level at $12.20, it is likely to go to the next support level at $11.53. Assuming the price breaks the second support level, the third support level stands at $11.06.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 1.30 billion has total of 76,883K Shares Outstanding. Its annual sales at the moment are 54,550 K in contrast with the sum of -193,570 K annual income. Company’s last quarter sales were recorded 7,890 K and last quarter income was -86,420 K.
